SEC Form DEFA14A filed by MoonLake Immunotherapeutics
$MLTX
Biotechnology: Pharmaceutical Preparations
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No. )
Securities Exchange Act of 1934
(Amendment No. )
|
Filed by the Registrant
|
☒
|
|
Filed by a Party other than the Registrant
|
☐
|
Check the appropriate box:
|
☐
|
Preliminary Proxy Statement
|
|
☐
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
|
☐
|
Definitive Proxy Statement
|
|
☒
|
Definitive Additional Materials
|
|
☐
|
Soliciting Material under §240.14a-12
|
MoonLake Immunotherapeutics
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement if other than the Registrant)
(Name of Person(s) Filing Proxy Statement if other than the Registrant)
Payment of Filing Fee (Check all boxes that apply):
|
☒
|
No fee required.
|
|
|
|
|
☐
|
Fee paid previously with preliminary materials.
|
|
|
|
|
☐
|
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.
|
Your Vote Counts!MOONLAKE IMMUNOTHERAPEUTICS2024 Annual General Meeting of ShareholdersVote by June 4, 202411:59 PMET
MOONLAKE IMMUNOTHERAPEUTICSDORFSTRASSE 29ZUG, SWITZERLAND 6300 You invested in MOONLAKE IMMUNOTHERAPEUTICS and it’s time to vote!You have the right to vote on proposals being presented at the Annual General Meeting of Shareholders. This is an
important notice regarding the availability of proxy materials for the shareholder meeting to be held on June 5, 2024.Get informed before you voteView the Notice, Proxy Statement and Annual Report online OR you can receive a free paper or email
copy of the material(s) by requesting prior to May 22, 2024. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to
[email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit
www.ProxyVote.comControl #Smartphone users Point your camera here and vote without entering a control number Vote in Person at the Meeting*June 5, 20248:00 a.m. Eastern TimeAt the offices of Gibson, Dunn & Crutcher LLPLocated at 200 Park
AvenueNew York, New York 10166 *Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares.
Vote at www.ProxyVote.comTHIS IS NOT A VOTABLE BALLOTThis is an overview of the more complete proxy materials that
are available to you on the Internet. You may view the proxy materials at www.ProxyVote.com or easily request a paper copy. We encourage you to access and review all of the important information contained in the proxy materials before voting.
Please follow the instructions on the reverse side to vote on these important matters.Voting ItemsBoard Recommends1. Election of the two Class II director nominees to serve until the 2027 Annual General Meeting of Shareholders and until their
successors are duly elected and qualified.ForNominees:01) Catherine Moukheibir02) Dr. Ramnik Xavier2. Ratification, by ordinary resolution, of the selection of Baker Tilly US, LLP as the Company’s independent registered public accounting firm
for the year ending December 31, 2024.For3. Approval of, on an advisory basis, the compensation of the Company’s named executive officers.For4. Non-binding advisory vote on the frequency of future advisory votes on executive
compensation.1YearNOTE: Such other business as may properly come before the meeting or any adjournment or postponement thereof.Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”.